These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 30606938)

  • 21. Long-term survival in a patient with advanced lung adenocarcinoma harboring synchronous EGFR exon 18 G719A and BRAF V600E mutations and treated with afatinib: a case report.
    Huang Q; Chen C; Hu S; Wu H; Yu D; Zhu X; Xue C; Wu Y; Tang J; Xie R; Ran F
    Anticancer Drugs; 2022 Jan; 33(1):e730-e733. PubMed ID: 34387589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature.
    Shi Y; Wang M
    Thorac Cancer; 2018 Dec; 9(12):1788-1794. PubMed ID: 30379401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low-dose afatinib: A case report.
    Iida Y; Kumasawa F; Shimizu T; Shintani Y; Takahashi N; Gon Y
    Thorac Cancer; 2020 Feb; 11(2):447-450. PubMed ID: 31779047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival.
    Chan RT
    Asia Pac J Clin Oncol; 2018 Mar; 14 Suppl 1():7-9. PubMed ID: 29508940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.
    Sekine A; Kato T; Iwasawa T; Baba T; Suido A; Sakuranaka H; Futaki M; Ogura T
    Intern Med; 2016; 55(17):2457-61. PubMed ID: 27580550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation?
    Wahab A; Kesari K; Chaudhary S; Khan M; Khan H; Smith S; Boumber Y
    Cancer Biol Ther; 2017 Dec; 18(12):940-943. PubMed ID: 29157085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel EGFR exon 21 indel mutation in lung adenocarcinoma and response to dacomitinib: A case report.
    Zhou T; Xiong Q; Hong C; Wang Q; Wang W; Xu C; Cai J;
    Medicine (Baltimore); 2022 Aug; 101(34):e30269. PubMed ID: 36042660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of afatinib and radiotherapy on a patient with lung adenocarcinoma with a rare EGFR extracellular domain M277E mutation and high PD-L1 expression.
    Lv D; Wang R; Wang X; Feng H
    J Cancer Res Ther; 2022 Apr; 18(2):587-589. PubMed ID: 35645132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
    Chung C
    J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
    Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
    Yang JC; Sequist LV; Geater SL; Tsai CM; Mok TS; Schuler M; Yamamoto N; Yu CJ; Ou SH; Zhou C; Massey D; Zazulina V; Wu YL
    Lancet Oncol; 2015 Jul; 16(7):830-8. PubMed ID: 26051236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intracranial Responses to Afatinib at Different Doses in Patients With EGFR-mutated Non-small-cell Lung Carcinoma and Brain Metastases.
    Wei YF; Lim CK; Tsai MS; Huang MS; Chen KY
    Clin Lung Cancer; 2019 May; 20(3):e274-e283. PubMed ID: 30930121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lung carcinoma with diffuse cystic lesions misdiagnosed as pulmonary langerhans cell histocytosis: a case report.
    Gui X; Ding J; Li Y; Yu M; Chen T; Huang M; Xiao Y
    BMC Pulm Med; 2020 Feb; 20(1):30. PubMed ID: 32019517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment exceeds expectations in a patient with non-small cell lung adenocarcinoma with an EGFR exon 20 mutation.
    McAuliffe A; Bindal P; Haley M; Vredenburgh J
    J Oncol Pharm Pract; 2020 Jan; 26(1):206-208. PubMed ID: 30760168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Afatinib is especially effective against non-small cell lung cancer carrying an EGFR exon 19 deletion.
    Banno E; Togashi Y; Kobayashi Y; Hayashi H; Mitsudomi T; Nishio K
    Anticancer Res; 2015 Apr; 35(4):2005-8. PubMed ID: 25862853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation.
    Tanaka M; Ishii H; Moribuchi H; Naito Y; Matsuo N; Nakamura M; Tokito T; Azuma K; Yamada K; Hoshino T
    Invest New Drugs; 2018 Aug; 36(4):715-717. PubMed ID: 29546681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report.
    Van Acker L; Stevens D; Vermaelen K; Surmont V
    J Med Case Rep; 2021 Nov; 15(1):562. PubMed ID: 34809713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma.
    Cao Y; Xu H; Liao M; Qu Y; Xu L; Zhu D; Wang B; Tian S
    Int J Clin Oncol; 2018 Apr; 23(2):249-257. PubMed ID: 28988295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple intraventricular metastases from lung adenocarcinoma with EGFR G719X mutation: a case report.
    Kong C; Zhou D; Wu N; Bai C
    BMC Pulm Med; 2020 May; 20(1):135. PubMed ID: 32393286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination therapy with afatinib and bevacizumab in an EGFR-mutated non-small cell lung cancer patient with acquired ERBB2 amplification: A case report.
    Chen S; Xiang T; Lu W; Hong S; Li Y; Lu Y; Zhang Q; Chen Y; Zhou S; Wang G; Zhang Z; Cai Y
    Medicine (Baltimore); 2021 Feb; 100(8):e24380. PubMed ID: 33663050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.